Ministry of Education Key Laboratory of Metabolism and Molecular Medicine, Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China; Life Sciences Institute and Department of Cell & Developmental Biology, University of Michigan Medical Center, Ann Arbor, MI, 48109, USA.
Life Sciences Institute and Department of Cell & Developmental Biology, University of Michigan Medical Center, Ann Arbor, MI, 48109, USA.
Mol Metab. 2019 Feb;20:128-137. doi: 10.1016/j.molmet.2018.12.004. Epub 2018 Dec 15.
Nonalcoholic steatohepatitis (NASH) is closely associated with metabolic syndrome and increases the risk for end-stage liver disease, such as cirrhosis and hepatocellular carcinoma. Despite this, the molecular events that influence NASH pathogenesis remain poorly understood. The objectives of the current study are to delineate the transcriptomic and proteomic signatures of NASH liver, to identify potential pathogenic pathways and factors, and to critically assess their role in NASH pathogenesis.
We performed RNA sequencing and quantitative proteomic analyses on the livers from healthy and diet-induced NASH mice. We examined the association between plasma levels of TSK, a newly discovered hepatokine, and NASH pathologies and reversal in response to dietary switch in mice. Using TSK knockout mouse model, we determined how TSK deficiency modulates key aspects of NASH pathogenesis.
RNA sequencing and quantitative proteomic analyses revealed that diet-induced NASH triggers concordant reprogramming of the liver transcriptome and proteome in mice. NASH pathogenesis is linked to elevated plasma levels of the hepatokine TSK, whereas dietary switch reverses NASH pathologies and reduces circulating TSK concentrations. Finally, TSK inactivation protects mice from diet-induced NASH and liver transcriptome remodeling.
Global transcriptomic and proteomic profiling of healthy and NASH livers revealed the molecular signatures of diet-induced NASH and dysregulation of the liver secretome. Our study illustrates a novel pathogenic mechanism through which elevated TSK in circulation promotes NASH pathologies, thereby revealing a potential target for therapeutic intervention.
非酒精性脂肪性肝炎(NASH)与代谢综合征密切相关,增加了终末期肝病(如肝硬化和肝细胞癌)的风险。尽管如此,影响 NASH 发病机制的分子事件仍知之甚少。本研究的目的是描绘 NASH 肝脏的转录组和蛋白质组特征,确定潜在的致病途径和因素,并批判性地评估它们在 NASH 发病机制中的作用。
我们对健康和饮食诱导的 NASH 小鼠的肝脏进行了 RNA 测序和定量蛋白质组学分析。我们检查了新发现的肝激素 TSK 的血浆水平与 NASH 病理学及其对小鼠饮食转换的反应之间的关联。使用 TSK 敲除小鼠模型,我们确定了 TSK 缺乏如何调节 NASH 发病机制的关键方面。
RNA 测序和定量蛋白质组学分析显示,饮食诱导的 NASH 在小鼠中引发肝脏转录组和蛋白质组的一致重编程。NASH 的发病机制与升高的血浆肝激素 TSK 水平有关,而饮食转换则逆转了 NASH 病理学并降低了循环 TSK 浓度。最后,TSK 失活可保护小鼠免受饮食诱导的 NASH 和肝脏转录组重塑的影响。
对健康和 NASH 肝脏的全基因组转录组和蛋白质组学分析揭示了饮食诱导的 NASH 的分子特征和肝脏分泌组的失调。我们的研究说明了一种新的致病机制,即循环 TSK 的升高促进了 NASH 病理学,从而揭示了一种潜在的治疗干预靶点。